EP Patent

EP3968980A1 — Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease

Assigned to Clexio Bioscience Ltd · Expires 2022-03-23 · 4y expired

What this patent protects

Provided are methods and compositions for treating nocturnal symptoms of Parkinson's disease, morning akinesia, or associated symptoms thereof in a human subject in need thereof, wherein circulating plasma levels of levodopa are provided for an extended period of time following a…

USPTO Abstract

Provided are methods and compositions for treating nocturnal symptoms of Parkinson's disease, morning akinesia, or associated symptoms thereof in a human subject in need thereof, wherein circulating plasma levels of levodopa are provided for an extended period of time following a period of delay after administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP3968980A1
Jurisdiction
EP
Classification
—
Expires
2022-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Clexio Bioscience Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.